Innovative Cell Therapy Firm Yimiao Shenzhou Signs Strategic Investment Deal with Beijing-Tianjin-Hebei Coordinated Development Industry Investment Fund
Imunopharm
Developer of Gene and Cell Therapy Technologies
On November 12, the 2024 Beijing-Tianjin-Hebei Fund and Enterprise Financing Matchmaking Conference was successfully held in Beijing Economic-Technological Development Area. Themed "Integrating Technology and Finance, Empowering Industrial Clusters," the event was hosted by the Joint Working Office for Beijing-Tianjin-Hebei Coordinated Development and the development and reform commissions of the three regions, and co-organized by the economic (industrial) information departments, science and technology departments, investment promotion departments of the three regions, as well as the Beijing Economic-Technological Development Area Management Committee. Liu Bozheng, member of the Party Leadership Group of the Beijing Municipal Development and Reform Commission and standing vice director of the Beijing Leading Group Office for Promoting Beijing-Tianjin-Hebei Coordinated Development, attended the conference and delivered a speech.
Beijing Yimiao Shenzhou Medical Technology Co., Ltd. ("Yimiao Shenzhou" for short), as a key project in corporate financing, was invited by the Beijing Development and Reform Commission to participate in this event and attended the signing ceremony to sign with the Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund.
Beijing Yimiaoshenzhou Medical Techology Co., Ltd. signing position is second from the left.
A relevant official from the Beijing Municipal Development and Reform Commission stated,The scale of funds participating in this year's financing matchmaking conference has exceeded 120, representing a 30% increase compared to last year.At the event, representatives of 17 Beijing-Tianjin-Hebei funds and 35 corporate representatives signed agreements on-site, with a total investment value reaching 3 billion yuan.Among them, the signed fund represents the Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund, jointly established by the three regions of Beijing, Tianjin, and Hebei in collaboration with the China Development Bank. The initial scale of the fund is 4.15 billion yuan. On-site signings were conducted with six projects, including Beijing Yimiaoshenzhou Medical Techology Co., Ltd., with intended investment amounting to 1.46 billion yuan.
It is reported that this event aims to further leverage the collaborative role of the three regional governments, deepen the cooperation among enterprises, funds, banks, industry associations, and innovation platforms in these areas, comprehensively support the development of the "six chains and five clusters" in the Beijing-Tianjin-Hebei region, promote a virtuous cycle of "technology-industry-finance," further activate the engine driving regional development, and jointly foster the growth of new productive forces.
This event attracted more than 550 participants, including representatives from relevant government departments, technology enterprises, investment funds, financial institutions, industry associations in the Beijing-Tianjin-Hebei region, as well as high-quality enterprises from the Yangtze River Delta, Guangdong-Hong Kong-Macao Greater Bay Area, and Chengdu-Chongqing regions.
// About Yimiao Shenzhou //
Founded in 2015 and headquartered in Beijing, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. is a leading clinical-stage biopharmaceutical company on a mission to "make cancer no longer an incurable disease." The company focuses on applying innovative gene and cell therapy technologies to the treatment of major diseases, including cancer and autoimmune disorders. To date, the company has completed nine rounds of strategic financing and owns a one-stop proprietary platform for gene and cell drug research, development, and commercialization. It holds multiple core technologies and was awarded the top prize in the finals of China's Disruptive Technology Innovation Competition. The company has received seven clinical trial approvals for Class 1 new drugs and obtained Beijing’s first-ever Manufacturing License for gene and cell therapies. Its R&D pipeline covers hematological cancers such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, and melanoma, positioning it as a leader in the gene and cell therapy sector.
The company has undertaken more than 10 national and provincial scientific research projects, including the Special Project of the National Key R&D Program by the Ministry of Science and Technology, the Major Innovation Project for Science and Technology under the National Health Commission’s "2030" initiative, the "Challenge Leader" technical project on cell therapy by the National Innovation Center, and the Beijing Municipal Science and Technology Major Special Project. It has obtained key qualifications such as a National High-tech Enterprise, a Beijing-based specialized, refined, distinctive, and innovative enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Haidian District Haiying Talent of Beijing, Xingguomen Leading Talent of Daxing District in Beijing, the Gold Award (First Place) at Tsinghua University President's Cup Innovation Challenge, MIT’s 35 Innovators Under 35, and Fortune Magazine’s 40 Under 40 Business Elites.
